Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients

被引：0
|
作者：
Zhang, L. [1 ]
Lu, S. [2 ]
Dechaphunkul, A. [3 ]
Chessari, S. [4 ]
Lanzarotti, C. [5 ]
Jordan, K. [6 ]
Aapro, M. [7 ]
机构：
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Prince Songkla Univ, Div Med Oncol, Hat Yai, Thailand
[4] Helsinn Healthcare, Corp Clin Dev, Lugano, Switzerland
[5] Helsinn Healthcare, Stat & Data Management, Lugano, Switzerland
[6] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[7] Clin Genolier, Multidisciplinary Oncol Inst, Ctr Canc, Genolier, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
    Lu, S.
    Zhang, L.
    Dechaphunkul, A.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1831 - S1832
  • [22] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [23] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
    Hesketh, Paul Joseph
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Alyasova, Anna
    Drobner, Igor
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Aapro, Matti
    Karthaus, Meinolf
    Schwartzberg, Lee
    Bondarenko, Igor
    Sarosiek, Tomasz
    Oprean, Cristina
    Cardona-Huerta, Servando
    Hansen, Vincent
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Rugo, Hope
    SUPPORTIVE CARE IN CANCER, 2017, 25 (04) : 1127 - 1135
  • [27] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Matti Aapro
    Meinolf Karthaus
    Lee Schwartzberg
    Igor Bondarenko
    Tomasz Sarosiek
    Cristina Oprean
    Servando Cardona-Huerta
    Vincent Hansen
    Giorgia Rossi
    Giada Rizzi
    Maria Elisa Borroni
    Hope Rugo
    Supportive Care in Cancer, 2017, 25 : 1127 - 1135
  • [28] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    Gralla, R. J.
    Bosnjak, S. M.
    Hontsa, A.
    Balser, C.
    Rizzi, G.
    Rossi, G.
    Borroni, M. E.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339
  • [29] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
  • [30] Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.
    Aapro, Matti S.
    Karthaus, Meinolf
    Schwartzberg, Lee Steven
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Palmas, Marco
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345